… biosimilars among fellow nurses is high. In order to increase their knowledge of biosimilars
and appropriately address patient … ant to raise patient awareness of biosimilars through ongo…

… Understanding the principles of biosimilar development and … not classified as biosimilars
in the United States. For instance, … ; NCT01519700) in patients with breast cancer treated with …

… knowledge that improves future transitions to biosimilars and … understanding as we navigated
COVID-19 hospital policies were greatly appreciated. I also express my gratitude to my co-…

… , contribution to biosimilar policy and level of expertise. Across … patient co-payments as an
instrument to favour biosimilar … to increase biosimilar uptake in areas like oncology, where …

… require considerable scientific expertise and monetary investment to … Co-existence of
noncomparator biologics and biosimilars in the … that are currently approved in Europe and the …

… of biosimilars and reasons for either prescribing biosimilars … to prescribe biosimilars among
specialist physicians in Korea. … , medical oncology, and surgical oncology. Most respondents (…

… The United States has fast been catching up, but with limited … knowledge and the medical
literature about the biosimilar, … be aware, pCOBI is a partnership between pCPA and Cancer …

… biosimilars, due to lack of knowledge. These findings are consistent with an incomplete
understanding of biosimilars… Drug Administration (FDA, the USA regulatory agency) that did not …

… on their knowledge of, and attitudes towards, biosimilars. The … the infliximab biosimilars now
gives oncologists a biosimilar … This study was funded by Merck & Co, they did not contribute …

… treatment of patients with breast or metastatic stomach cancer (… authorities possessing the
appropriate expertise could stand as a … and co-development strategies to facilitate the entry of …